Inactive Instrument

Ligand Pharmaceuticals Inc. Stock OTC Bulletin Board

Equities

US53220K1815

Pharmaceuticals

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Ligand Pharmaceuticals Inc.
Sales 2024 * 149M Sales 2025 * 169M Capitalization 1.76B
Net income 2024 * 96M Net income 2025 * 61M EV / Sales 2024 * 11.8 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 10.4 x
P/E ratio 2024 *
18.9 x
P/E ratio 2025 *
27.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.65%
More Fundamentals * Assessed data
Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties MT
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024 CI
Ligand Pharmaceuticals Incorporated entered into an agreement to acquire APEIRON Biologics AG for $128 million. CI
Invios GmbH announced that it expects to receive $4 million in funding from Ligand Pharmaceuticals Incorporated CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Defensive Index CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000 Growth Index CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Value-Defensive Index CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000E Growth Index CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Growth Index CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2500 Growth Index CI
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell Small Cap Comp Growth Index CI
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease MT
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults CI
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing MT
More news
Managers TitleAgeSince
Chief Executive Officer 63 07-02-28
Director of Finance/CFO 53 22-10-31
President 49 15-08-05
Members of the board TitleAgeSince
Chairman 74 03-02-28
Director/Board Member 74 11-01-31
Director/Board Member 64 08-08-03
More insiders
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Related indices
More about the company